Biodesix (NASDAQ:BDSX – Get Free Report) had its price objective lowered by equities research analysts at HC Wainwright from $38.00 to $34.00 in a report issued on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright‘s price target would suggest a potential upside of 239.32% from the company’s previous close.
Other research analysts also recently issued reports about the company. Canaccord Genuity Group boosted their price target on Biodesix from $27.00 to $35.00 and gave the company a “buy” rating in a report on Monday, August 10th. Weiss Ratings upgraded Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, September 8th. Finally, TD Cowen reaffirmed a “buy” rating and set a $40.00 price objective (up from $30.00) on shares of Biodesix in a research note on Tuesday, October 13th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.20.
Get Our Latest Report on Biodesix
Biodesix Stock Performance
Biodesix (NASDAQ:BDSX – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported ($0.75) EPS for the quarter, hitting analysts’ consensus estimates of ($0.75). The firm had revenue of $24.04 million for the quarter, compared to the consensus estimate of $27.48 million. Biodesix had a negative return on equity of 513.78% and a negative net margin of 25.74%. On average, equities analysts forecast that Biodesix will post -2.81 earnings per share for the current year.
Institutional Investors Weigh In On Biodesix
Several hedge funds have recently modified their holdings of BDSX. HighTower Advisors LLC purchased a new position in shares of Biodesix in the 3rd quarter valued at about $228,000. AIGH Capital Management LLC boosted its position in Biodesix by 1.1% during the third quarter. AIGH Capital Management LLC now owns 686,021 shares of the company’s stock worth $20,464,000 after purchasing an additional 7,693 shares in the last quarter. Squarepoint Ops LLC purchased a new position in Biodesix during the second quarter worth approximately $354,000. Bank of America Corp DE purchased a new position in Biodesix during the second quarter worth approximately $603,000. Finally, Allworth Financial LP acquired a new stake in Biodesix in the second quarter valued at approximately $112,000. 20.96% of the stock is owned by hedge funds and other institutional investors.
Biodesix Company Profile
Biodesix, Inc. is a data-driven diagnostic solutions company focused on improving the diagnosis and treatment of lung diseases, including lung cancer. The company combines proprietary molecular diagnostic technologies, clinical data, and artificial intelligence to help physicians assess disease risk and make more informed treatment decisions. Its offerings include blood-based tests designed to help evaluate indeterminate pulmonary nodules, identify patients who may be at higher risk of lung cancer, and support treatment selection and monitoring.
Further Reading
- Five stocks we like better than Biodesix
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Biodesix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodesix and related companies with MarketBeat.com's FREE daily email newsletter.
